Variable benefits packages for HCT may directly affect outcomes of patients undergoing transplant, according to a new report from the National Marrow Donor Program-sponsored System Capacity Initiative. After reviewing benefits packages from public and private payers, the group reached a consensus opinion and outlined a recipient benefit package that avoids major coverage gaps that could negatively affect transplant patient outcomes. The authors note that the working group’s recommendation was “to encourage adoption of these benefits at a national level by payers, benefit brokers/consultants, and sales teams.”
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Consensus Report: Optimal Benefits Packages for HCT Focused on Outcomes
Aug 2014